期刊
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
卷 30, 期 4, 页码 S15-S19出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urolonc.2011.09.003
关键词
Prostate cancer; Castration-resistant prostate cancer (CRPC); Chemotherapy; Toxicity; Mitoxantrone; Docetaxel; Cabazitaxel; Zoledronic acid
资金
- NIH, National Cancer Institute, Center for Cancer Research
Prostate cancer (CaP) continues to be a significant burden on men's health. While significant advances have been made in the diagnosis and treatment of localized disease, androgen deprivation therapy remains the treatment of choice for advanced and metastatic disease. However, once a man progresses on androgen deprivation, therapies targeting castration-resistant CaP have been extremely limited until quite recently. Urologic oncologists who wish to play an active role in the treatment of men with CaP from diagnosis through end-of-life care should be familiar with administration of and toxicities associated with chemotherapeutic agents. This review is directed at urologists and urologic oncologists and will discuss many of the FDA-approved intravenous agents currently available for castration-resistant CaP with a specific focus on the side-effects associated with these regimens. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据